Literature DB >> 27873565

Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.

R H V Pereira1, R S Leão1, A P Carvalho-Assef2, R M Albano3, E R A Rodrigues1, M C Firmida1, T W Folescu4, M C Plotkowski1, V G Bernardo3, E A Marques1.   

Abstract

Achromobacter spp. are opportunistic pathogens increasingly recovered from adult patients with cystic fibrosis (CF). We report the characterization of 122 Achromobacter spp. isolates recovered from 39 CF patients by multilocus sequence typing, virulence traits, and susceptibility to antimicrobials. Two species, A. xylosoxidans (77%) and A. ruhlandii (23%) were identified. All isolates showed a similar biofilm formation ability, and a positive swimming phenotype. By contrast, 4·3% and 44·4% of A. xylosoxidans and A. ruhlandii, respectively, exhibited a negative swarming phenotype, making the swimming and swarming abilities of A. xylosoxidans significantly higher than those of A. ruhlandii. A. xylosoxidans isolates from an outbreak clone also exhibited significantly higher motility. Both species were generally susceptible to ceftazidime, ciprofloxacin, imipenem and trimethoprim/sulphamethoxazole and there was no significant difference in susceptibility between isolates from chronic or sporadic infection. However, A. xylosoxidans isolates from chronic and sporadic cases were significantly more resistant to imipenem and ceftazidime than isolates of the outbreak clone.

Entities:  

Keywords:  zzm321990 Achromobacterzzm321990 ; clinical microbiology; cystic fibrosis

Mesh:

Substances:

Year:  2016        PMID: 27873565      PMCID: PMC9507688          DOI: 10.1017/S0950268816002624

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  36 in total

Review 1.  Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure.

Authors:  Søren Molin; Tim Tolker-Nielsen
Journal:  Curr Opin Biotechnol       Date:  2003-06       Impact factor: 9.740

2.  Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study.

Authors:  Christine Rønne Hansen; Tacjana Pressler; Niels Høiby; Magdalena Gormsen
Journal:  J Cyst Fibros       Date:  2006-06-13       Impact factor: 5.482

Review 3.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.

Authors:  Yongfei Hu; Yuying Zhu; Yanan Ma; Fei Liu; Na Lu; Xi Yang; Chunguang Luan; Yong Yi; Baoli Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

5.  Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.

Authors:  C R Hansen; T Pressler; K G Nielsen; P Ø Jensen; T Bjarnsholt; N Høiby
Journal:  J Cyst Fibros       Date:  2009-11-25       Impact factor: 5.482

6.  Swarming motility: a multicellular behaviour conferring antimicrobial resistance.

Authors:  Sandra Lai; Julien Tremblay; Eric Déziel
Journal:  Environ Microbiol       Date:  2008-09-11       Impact factor: 5.491

7.  Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance.

Authors:  Joerg Overhage; Manjeet Bains; Michelle D Brazas; Robert E W Hancock
Journal:  J Bacteriol       Date:  2008-02-01       Impact factor: 3.490

8.  Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

Authors:  Thomas Bjarnsholt; Peter Østrup Jensen; Mark J Fiandaca; Jette Pedersen; Christine Rønne Hansen; Claus Bøgelund Andersen; Tacjana Pressler; Michael Givskov; Niels Høiby
Journal:  Pediatr Pulmonol       Date:  2009-06

9.  Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer.

Authors:  German Matías Traglia; Marisa Almuzara; Andrea Karina Merkier; Christina Adams; Laura Galanternik; Carlos Vay; Daniela Centrón; María Soledad Ramírez
Journal:  Curr Microbiol       Date:  2012-08-28       Impact factor: 2.188

10.  Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes.

Authors:  Tim Holm Jakobsen; Martin Asser Hansen; Peter Østrup Jensen; Lars Hansen; Leise Riber; April Cockburn; Mette Kolpen; Christine Rønne Hansen; Winnie Ridderberg; Steffen Eickhardt; Marlene Hansen; Peter Kerpedjiev; Morten Alhede; Klaus Qvortrup; Mette Burmølle; Claus Moser; Michael Kühl; Oana Ciofu; Michael Givskov; Søren J Sørensen; Niels Høiby; Thomas Bjarnsholt
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

View more
  12 in total

1.  Distribution of Achromobacter Species in 12 French Cystic Fibrosis Centers in 2020 by a Retrospective MALDI-TOF MS Spectrum Analysis.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Anaïs Folletet; Julien Bador; Maryam Abid; Marlène Amara; Clémence Beauruelle; Olivier Belmonte; Pierre Boyer; Emilie Cardot-Martin; Anne-Gaëlle Cauchie; Sylvie Colin de Verdière; Claire Daurel; Cécile Gaudru; Farida Hamdad; Geneviève Héry-Arnaud; Baptiste Hoellinger; Claudie Lamoureux; Marie-Frédérique Lartigue; Damasie Malandain; Océane Marchand; Caroline Piau; Sandrine Picot; Hélène Revillet; Zeina Sabouni; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2022-05-05       Impact factor: 11.677

Review 2.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

3.  Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Achromobacter Species from Cystic Fibrosis Patients.

Authors:  Ijeoma N Okoliegbe; Karolin Hijazi; Kim Cooper; Corinne Ironside; Ian M Gould
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 4.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

5.  Duplex real-time PCR assay for the simultaneous detection of Achromobacter xylosoxidans and Achromobacter spp.

Authors:  Erin P Price; Valentina Soler Arango; Timothy J Kidd; Tamieka A Fraser; Thuy-Khanh Nguyen; Scott C Bell; Derek S Sarovich
Journal:  Microb Genom       Date:  2020-07-15

6.  A putative enoyl-CoA hydratase contributes to biofilm formation and the antibiotic tolerance of Achromobacter xylosoxidans.

Authors:  Lydia C Cameron; Benjamin Bonis; Chi Q Phan; Leslie A Kent; Alysha K Lee; Ryan C Hunter
Journal:  NPJ Biofilms Microbiomes       Date:  2019-08-06       Impact factor: 7.290

7.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Rapid Detection of Isolates Belonging to the Epidemic Clones Achromobacter xylosoxidans ST137 and Achromobacter ruhlandii DES from Cystic Fibrosis Patients.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Angélique Chapuis; Véronique Varin; Julien Bador; Nadia Makki; Lise Cremet; Elise Persyn; Emilie Cardot-Martin; Fedoua Echahidi; Charlotte Peeters; Denis Pierard; Peter Vandamme; Alexia Verroken; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2021-08-04       Impact factor: 5.948

8.  Chronic osteomyelitis caused by Achromobacter xylosoxidans following orthopaedic trauma: A case report and review of the literature.

Authors:  Sahand Imani; Asanka Wijetunga; Sarah Shumborski; Edmund O'Leary
Journal:  IDCases       Date:  2021-06-29

9.  First Documented Case of Percutaneous Endoscopic Gastrostomy (PEG) Tube-Associated Bacterial Peritonitis due to Achromobacter Species with Literature Review.

Authors:  Nishant Tripathi; Niki Koirala; Hirotaka Kato; Tushi Singh; Kishore Karri; Kshitij Thakur
Journal:  Case Rep Gastrointest Med       Date:  2020-01-16

10.  In Vitro Activity of 22 Antibiotics against Achromobacter Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?

Authors:  Clémence Beauruelle; Claudie Lamoureux; Arsid Mashi; Sophie Ramel; Jean Le Bihan; Thomas Ropars; Anne Dirou; Anandadev Banerjee; Didier Tandé; Hervé Le Bars; Geneviève Héry-Arnaud
Journal:  Microorganisms       Date:  2021-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.